Peer-reviewed veterinary case report
Clinical signs and survival in Japanese dogs with histiocytic sarcoma
By Takahashi, Masashi et al.·Published in The Journal of veterinary medical science·2014·Department of Veterinary Internal Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical characteristics and prognostic factors in dogs with histiocytic sarcomas in Japan.
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with histiocytic sarcoma, a rare type of cancer, were studied to understand their symptoms and treatment outcomes. The most affected breeds included Flat-Coated Retrievers, Pembroke Welsh Corgis, and Bernese Mountain Dogs. Dogs that received surgery or chemotherapy had a median survival time of 85 days, while those that did not receive treatment lived only about 12 days on average. Factors like low platelet counts and not receiving treatment were linked to shorter survival times. This highlights the importance of prompt treatment for better outcomes in dogs with this condition.
People also search for: dog histiocytic sarcoma treatment · Flat-Coated Retriever cancer prognosis · Pembroke Welsh Corgi tumor survival rate
Abstract
Canine histiocytic sarcoma (HS) is a rare neoplasm that originates from dendritic cells or macrophages, and there have been a number of cases experienced in Japan. To identify the characteristics and prognostic variables that determine outcome in dogs with HS in Japan, medical records of 73 dogs with HS were retrospectively analyzed. Signalment, clinical signs, complete blood count (CBC), blood chemistry profiles, treatment, response to treatment and overall survival (OS) were analyzed. Diagnosis of HS was determined histologically in 44 cases and cytologically in 29 cases. The most frequently diagnosed breeds were Flat-Coated Retrievers (n=16, odds ratio [OR] 62.0), Pembroke Welsh corgis (n=15, OR 9.7) and Bernese Mountain dogs (n=14, OR 45.0). Median survival time for all dogs in this study was 43 days. In the dogs that received no treatment or only symptomatic treatment, the median OS was 12 days (range 2-254 days) compared with that of dogs that received surgical treatment and/or chemotherapy (85 days, range 4-360 days). Univariate analysis identified anemia, thrombocytopenia, hypoalbuminemia, hypoproteinemia and not receiving antitumor treatment (chemotherapy and/or surgery) as factors significantly associated with shorter OS. Multivariate analysis confirmed that platelet counts, localized/disseminated lesional pattern and whether the dog received antitumor treatment were significantly predictive of survival.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24441652/